Details of the Drug

General Information of Drug (ID: DMZA2K0)

Drug Name
INCSHR1210
Synonyms Camrelizumab
Indication
Disease Entry ICD 11 Status REF
Bronchioalveolar carcinoma 2C25.0 Phase 3 [1]
Esophageal squamous cell carcinoma 2E60.1 Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0BO0K
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bronchioalveolar carcinoma
ICD Disease Classification 2C25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)